Nanoliposomal irinotecan plus fluorouracil and folinic acid in irinotecan-pretreated vs. -naive pancreatic cancer patients: A retrospective cohort study

被引：0
|
作者：
Schoenlein, M. [1 ]
Stein, A. [1 ,2 ]
Tintelnot, J. [1 ]
Nilsson, S. [1 ]
Reichelt, R. [3 ]
Borchardt, J. [3 ]
Schnell, R. [4 ]
Goekkurt, E. [1 ,2 ]
Bokemeyer, C. [1 ]
Sinn, M. [1 ]
机构：
[1] Univ Klinikum Hamburg Eppendorf, Med Klin & Poliklin Onkol Hamatol & Knochenmarktr, Abt Pneumol, Hamburg, Germany
[2] Hematol Oncol Practice Hamburg HOPE, Hamburg, Germany
[3] Onkotrakt AG, Hamburg, Germany
[4] Pioh Koln Nord Studien GbR, Cologne, Germany
来源：
ONCOLOGY RESEARCH AND TREATMENT | 2021年 / 44卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
ep601
引用
收藏
页码：224 / 225
页数：2
相关论文
共 50 条
  • [31] Bimonthly Chemotherapy with Oxaliplatin, Irinotecan, Infusional 5-Fluorouracil/Folinic Acid in Patients with Metastatic Colorectal Cancer Pretreated with Irinotecan- or Oxaliplatin-Based Chemotherapy
    Nobili, S.
    Checcacci, D.
    Filippelli, F.
    Del Buono, S.
    Mazzocchi, V.
    Mazzei, T.
    Mini, E.
    JOURNAL OF CHEMOTHERAPY, 2008, 20 (05) : 622 - 631
  • [32] A real-world prospective analysis of the relationship between nanoliposomal irinotecan and fluorouracil with folinic acid and neutropenia in patients with pancreatic cancer (NAPOLEON-2 study, NN-2401).
    Shirakawa, Tsuyoshi
    Araki, Tomonori
    Shimokawa, Mototsugu
    Otsuka, Taiga
    Nakazawa, Junichi
    Shimokawa, Hozumi
    Koga, Futa
    Oda, Hisanobu
    Takeshita, Shigeyuki
    Arima, Shiho
    Arita, Shuji
    Kawaguchi, Yasunori
    Nishikawa, Kazuo
    Taguchi, Hiroki
    Jikuya, Kenichi
    Sakai, Tatsunori
    Ueda, Yujiro
    Sakae, Takahiro
    Mizuta, Toshihiko
    Mitsugi, Kenji
    JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (4_SUPPL) : 762 - 762
  • [33] Neoadjuvant treatment of unresectable liver disease with irinotecan and 5-fluorouracil plus folinic acid in colorectal cancer patients
    Pozzo, C
    Basso, M
    Cassano, A
    Quirino, A
    Schinzari, G
    Trigila, N
    Vellone, M
    Giuliante, F
    Nuzzo, G
    Barone, C
    ANNALS OF ONCOLOGY, 2004, 15 (06) : 933 - 939
  • [34] Irinotecan Plus Gemcitabine and Fluorouracil in Advanced Biliary Tract Cancer: A Retrospective Study
    Endlicher, Esther
    Schnoy, Elisabeth
    Troppmann, Martina
    Rogler, Gerhard
    Messmann, Helmut
    Klebl, Frank
    Gelbmann, Cornelia
    Kullmann, Frank
    DIGESTION, 2016, 93 (03) : 229 - 233
  • [35] Efficacy of third-line chemotherapy after liposomal irinotecan and fluorouracil with folinic acid for pancreatic cancer
    Kawasaki, Reina
    Shirakawa, Tsuyoshi
    Shimokawa, Mototsugu
    Otsuka, Taiga
    Oda, Hisanobu
    Shibuki, Taro
    Nakazawa, Junichi
    Arima, Shiho
    Miwa, Keisuke
    Koga, Futa
    Kubotsu, Yoshihito
    Ueda, Yujiro
    Shimokawa, Hozumi
    Takeshita, Shigeyuki
    Komori, Azusa
    Hosokawa, Ayumu
    Sakai, Tatsunori
    Arita, Shuji
    Mizuta, Toshihiko
    Mitsugi, Kenji
    ANNALS OF ONCOLOGY, 2023, 34 : S1435 - S1435
  • [36] Multicenter observational study of nanoliposomal irinotecan and fluorouracil/leucovorin in patients with unresectable or recurrent pancreatic cancer (NAPOLEON-2): Final retrospective results.
    Imajima, Takashi
    Shirakawa, Tsuyoshi
    Shimokawa, Mototsugu
    Otsuka, Taiga
    Shibuki, Taro
    Nakazawa, Junichi
    Arima, Shiho
    Miwa, Keisuke
    Koga, Futa
    Kubotsu, Yoshihito
    Ueda, Yujiro
    Hosokawa, Ayumu
    Takeshita, Shigeyuki
    Shimokawa, Hozumi
    Komori, Azusa
    Oda, Hisanobu
    Sakai, Tatsunori
    Arita, Shuji
    Mizuta, Toshihiko
    Mitsugi, Kenji
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 : 706 - 706
  • [37] Nanoliposomal irinotecan with 5-fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy: A real-world experience
    Yu, Hung-Yuan
    Lee, Chun-Yang
    Lin, Le-Gin
    Chao, Yee
    Li, Chung-Pin
    JOURNAL OF THE CHINESE MEDICAL ASSOCIATION, 2022, 85 (01) : 42 - 50
  • [38] CAPIRI (capecitabine, irinotecan) plus bevacizumab vs FOLFIRI (folinic acid, 5 fluorouracil, irinotecan) plus bevacizumab for the treatment of patients with metastatic colorectal cancer (mCRC): Interim analysis for safety of a randomized phase III trial
    Ziras, N.
    Polyzos, A.
    Kakolyris, S.
    Xenidis, N.
    Kentepozidis, N.
    Athanasiadis, A.
    Stergiou, I.
    Androulakis, N.
    Vamvakas, L.
    Souglakos, J.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [39] Oxaliplatin with high-dose leucovorin and infusional 5-fluorouracil in irinotecan-pretreated patients with advanced colorectal cancer (ACC)
    Kouroussis, C
    Souglakos, J
    Mavroudis, D
    Papadouris, S
    Kakolyris, S
    Agelaki, S
    Kalbakis, K
    Panopoulos, C
    Vardakis, N
    Sarra, E
    Georgoulias, V
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2002, 25 (06): : 627 - 631
  • [40] Survival predictors in pancreatic cancer patients on liposomal irinotecan plus fluorouracil/leucovorin: A multicenter observational study
    Keum, J.
    Lee, H. S.
    Park, C. S.
    Kim, J.
    Jang, W.
    Shin, K. I.
    Kang, H.
    Lee, S. H.
    Jo, J. H.
    Jang, S-I.
    Chung, M. J.
    Park, J. Y.
    Park, S. W.
    Cho, J. H.
    Bang, S.
    ANNALS OF ONCOLOGY, 2024, 35 : S143 - S143
12345